An 11,000-isolate same plate/same day comparison of the 3 most widely used platforms for analyzing multidrug-resistant clinical pathogens

L. E. Nielsen*, R. J. Clifford, Y. Kwak, L. Preston, C. Argyros, R. Rabinowitz, P. Waterman, E. Lesho

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Stewardship of the dwindling number of effective antibiotics relies on accurate phenotyping. We sought to conduct the first large-scale, same plate and day comparison of the 3 most widely used bacterial analyzers. A total of 11,020 multidrug-resistant clinical isolates corresponding to more than 485,000 data points were used to compare the 3 major identification and antibiotic susceptibility testing (AST) platforms. Bacterial suspensions, prepared from a single plate, were simultaneously tested on all platforms in the same laboratory. Discrepancies were derived from MIC values using 2014 interpretive guidelines. Molecular methods and manual microbroth dilution were reference standards. Most discrepancies were due to drug-organism-AST platform combination instead of individual factors. MicroScan misidentified Acinetobacter baumannii (P<0.001) and underestimated carbapenem susceptibility in Klebsiella pneumoniae. Vitek-2 and Phoenix had higher discrepancies for blaKPC-containing Enterobacteriaceae (P<0.05) and reported false susceptibilities more often. While all platforms performed according to standards, each had strengths and weaknesses for organism identification, assaying specific drug-organism combinations and inferring carbapenemase production.

Original languageEnglish
Pages (from-to)93-98
Number of pages6
JournalDiagnostic Microbiology and Infectious Disease
Volume83
Issue number2
DOIs
StatePublished - 1 Oct 2015
Externally publishedYes

Keywords

  • Antibiotics
  • Carbapenemase
  • MicroScan
  • Phoenix
  • Vitek-2

Fingerprint

Dive into the research topics of 'An 11,000-isolate same plate/same day comparison of the 3 most widely used platforms for analyzing multidrug-resistant clinical pathogens'. Together they form a unique fingerprint.

Cite this